Please login to the form below

cardiovascular drug

This page shows the latest cardiovascular drug news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

Novo looking to challenge with oral semaglutide. Eli Lilly has put the flesh on the bones of its REWIND cardiovascular outcomes study for diabetes drug Trulicity, a key element in its ... period. More than 46% of participants were women, and less than a

Latest news

UK heart deaths rise for first time in 50 years

Meanwhile, drug giants such as Novartis and AstraZeneca are developing new heart disease treatments, with the latter recently revealing that its antiplatelet drug Brilinta can reduce cardiovascular events in diabetes patients ... Novartis said it will
Stream on

In the healthcare model, this is not the case. I don’t pay you a fixed amount for a limitless supply of cardiovascular drug and also get a limitless supply of ... I only get access to a limitless supply of your cardiovascular drug.
J&J’s Invokana first SGLT2 to show kidney disease benefits

study,” said James List, Global Therapeutic Area Head, Cardiovascular &Metabolism, Janssen Research &Development. ... The drug also reduced the risk of cardiovascular (CV) death and hospitalisation for heart failure by 31%, major adverse CV events by 20
Amgen and UCB’s Evenity finally approved, but with label warnings

However, the drug comes with some cardiovascular safety risks, and it is these that have delayed its arrival on the market, and subsequent label warnings are certain to limit its use. ... Evenity also carries a boxed warning on its label, which advises
AZ says Brilinta hits the mark in diabetic heart disease

The drug can reduce cardiovascular events in diabetics with CAD. AstraZeneca has chalked up another clinical trial win for its antiplatelet drug Brilinta, showing that it can reduce cardiovascular events in ... It’s not all been positive for Brilinta

More from news
Approximately 2 fully matching, plus 83 partially matching documents found.

Latest Intelligence

Perfecting the pharmaceutical pipeline with AI

For example, a drug being used for cardiovascular disease might be found to have useful qualities for neurological diseases. ... We’re already seeing evidence of how AI can positively impact drug discovery.
Going the distance

Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... centric means that you need to think about your patients
Interview: Peter Meeus, Novo Nordisk

Several obstacles stand in the way of the uptake of Tresiba in Europe, including the decision from the US FDA to request more data from Novo Nordisk regarding the drug's ... cardiovascular safety before it can be approved.
Pharma deals during October 2012

In return for granting Merck a global exclusive licence to its cardiovascular drug candidates, Theravance will receive $153m in R&D funding and milestone payments, including a $5m upfront payment and ... and manufacturing partner. Quillivant XR is based
Pharma deals during July 2012

These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... 168. Vestiq / BioAlliance (a). Licence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Sanifit appoints Alexander Gold chief medical officer

Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others. ... A cardiologist with over 16 years experience of drug
Senior AstraZeneca exec jumps ship to small biotech

AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. . ... Meanwhile Elisabeth Björk, an associate professor of medicine at Uppsala university and leads
Milestone names chief medical officer

Cardiovascular specialist Milestone Pharmaceuticals has appointed experienced pharma researcher Dr Francis Plat as its new chief medical officer. ... Milestone's CEO Philippe Douville said: "Dr Plat is the perfect candidate for our development program
Jonathan Fox leaves AstraZeneca for MyoKardia

He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee. ... By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments,

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Packer Forbes News November 2015

A graduate from the University of Bath, Lydia’s study areas included Cardiovascular Pharmacology, Regenerative Medicine, Drug Targets in the Immune System with her dissertation focusing on the possibility of a

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.